Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - Other
Ratios

Apellis Pharmaceuticals (APLS) Receivables - Other (2022 - 2025)

Apellis Pharmaceuticals has reported Receivables - Other over the past 4 years, most recently at $496000.0 for Q4 2025.

  • Quarterly results put Receivables - Other at $496000.0 for Q4 2025, down 89.04% from a year ago — trailing twelve months through Dec 2025 was $496000.0 (down 89.04% YoY), and the annual figure for FY2025 was $496000.0, down 89.04%.
  • Receivables - Other for Q4 2025 was $496000.0 at Apellis Pharmaceuticals, down from $6.5 million in the prior quarter.
  • Over the last five years, Receivables - Other for APLS hit a ceiling of $6.5 million in Q3 2025 and a floor of $496000.0 in Q4 2025.
  • Median Receivables - Other over the past 4 years was $4.4 million (2024), compared with a mean of $3.7 million.
  • Biggest five-year swings in Receivables - Other: surged 181.72% in 2024 and later tumbled 89.04% in 2025.
  • Apellis Pharmaceuticals' Receivables - Other stood at $1.4 million in 2022, then surged by 111.79% to $3.1 million in 2023, then surged by 48.17% to $4.5 million in 2024, then tumbled by 89.04% to $496000.0 in 2025.
  • The last three reported values for Receivables - Other were $496000.0 (Q4 2025), $6.5 million (Q3 2025), and $5.9 million (Q2 2025) per Business Quant data.